Rules/misleading presentation/US-MIS-025

Claims should not rest on speculation, belief, or a poorly designed or conducted study

AI-verifiedblockerFDA guidance · non-bindingRaised as a question — a person decides

Rule

A communication based on speculation or belief without scientific support, or on a poorly designed or conducted study, is not consistent with FDA's recommendations even if the communication discloses that lack of support.

Check

Identify the evidentiary basis for each claim; confirm it is a real, adequately designed/conducted study rather than speculation. A violation looks like an unsupported or study-free assertion, disclaimers notwithstanding.

Escalate when

Always — requires evaluation of underlying study design/conduct quality.

Where this comes from

Q.6/A.6 · page 16. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…ion represented or suggested that the results on the individual components are demonstrated additional effects of the drug, disclosing the limitations of the underlying evidence would not correct the misleading message conveyed by the communication. Rather, as previously mentioned, the information should be presented in a way that does not overstate the conclusions that can be drawn from the supporting evidence. And if a firm’s communication is based on speculation or belief without scientific support or is based on a poorly designed or conducted study or analysis, that communication would not be consistent with the recommendations in this guidance, regardless of whether the communication discloses the lack of appropriate support for the information being presented. Q.7. What other considerations apply to CFL promotional communications that are consistent with the FDA-required labeling? A.7. In addition to the considerations addressed in Q.6/A.6, firms should ensure their FDA-regulated promotional materials otherwise satisfy the applicable requirements of the FD&C Act and FDA’s implementing regulations. Contains Nonbinding Recommendations Noth…

Open the original at page 16 on fda.gov ↗Read our full copy →

Document: FDA guidance: Medical Product Communications that Are Consistent With the FDA-Required Labeling – Questions and Answers (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: 1a18b7f242bfbbf897f198df…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

Basisconsistent-with-labeling

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is verbatim from the closing sentence of A.6 and directly establishes the substance: a communication based on speculation or belief without scientific support, or on a poorly designed or conducted study or analysis, 'would not be consistent with the recommendations in this guidance, regardless of whether the communication discloses the lack of appropriate support'.
- The rule statement is correctly hedged and matches the source. The title, however, converts a non-binding recommendation into an obligation: 'Claims must not be based on speculation, belief, or a poorly designed/conducted study'. The source says such a communication 'would not be consistent with the recommendations in this guidance' — it does not say it is prohibited. This is the classic overstatement failure, and the title is what a reviewer sees first.
- Atomic: the two triggers (speculation/belief without scientific support; poorly designed or conducted study) are alternative ways of failing one requirement — that the claim rest on adequate scientific support — and the Check applies a single test. Acceptable as one rule.
- 'judgment' is correct — 'poorly designed or conducted' is an adequacy assessment.
- 'guidance' is correct for authority. Severity 'blocker' sits above its siblings from the same paragraph (warning), but is defensible: a claim with no scientific basis at all cannot be cured by rewording or a disclosure, so halting the piece is the right outcome.
- applies_when omits the basis: consistent-with-labeling limit carried by sibling rule US-SUB-008 from the same answer; locator Q.6/A.6 is correct.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is a complete conditional clause with its own subject and consequence, taken from the closing sentence of Q.6/A.6, and the rule tracks it closely.
- Not overstated — and notably careful: the rule keeps FDA's own consequence ('is not consistent with FDA's recommendations') rather than inflating it to 'prohibited' or 'violates the FD&C Act,' and preserves the source's point that disclosure of the lack of support does not cure the problem.
- Atomic: speculation-without-scientific-support and a poorly designed or conducted study are two alternative triggers of one requirement (a claim must rest on adequate scientific support), not two independent obligations a piece must separately satisfy.
- Determinism 'judgment' is correct: assessing whether a study is poorly designed or conducted, or whether an assertion is speculation, is an evaluative call.
- Authority 'guidance' matches the source and the rule claims no more than the guidance does. Severity 'blocker' is defensible because the source says disclosure cannot cure it, so the defect cannot be fixed by adding a disclaimer. Locator and applies_when are correct.

Nearby rules

US-MIS-022 US-MIS-023 US-MIS-024 US-MIS-056 US-SUB-008